This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:food:aim_health:aging [02.09.2019] – [with additional studies] sallieq | home:food:aim_health:aging [02.11.2019] – [with additional studies] sallieq | ||
---|---|---|---|
Line 8: | Line 8: | ||
===== with additional studies ===== | ===== with additional studies ===== | ||
- | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | + | |
- | + | ||
- | Although uncontrolled confounding might still exist, olmesartan does not seem to increase cardiovascular risk compared with losartan. (({{pubmed> | + | |
The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | The ROADMAP study will answer the question whether an ARB can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. (({{pubmed> | ||
Line 18: | Line 16: | ||
The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. (({{pubmed> | ||
- | Therapeutic and supratherapeutic | + | Therapeutic and supratherapeutic |
+ | |||
+ | In conclusion, there is no robust signal for harm with olmesartan use. (({{pubmed> | ||
==== General research on aging ==== | ==== General research on aging ==== |